The maintenance treatment of advanced colorectal cancer with the Spleen and Spleen Relief Formula Colorectal cancer is the third most common malignant tumor worldwide, and about 15-25% of patients are already in advanced stage at the time of initial diagnosis, i.e. metastatic colorectal cancer (mCRC), which is inoperable, and the other 50% have recurrent metastases after surgery, and their 5-year survival rate is only 8%. FOLFIRI and XELOX as the first-line treatment option for mCRC. Several large clinical studies have demonstrated that first-line chemotherapy in combination with bevacizumab or cetuximab in mCRC patients with wild-type RAS achieved a median progression-free survival (mPFS) of 10.8 months and an overall survival (OS) of more than 30 months. mCRC chemotherapy is traditionally conceived as continuous treatment until disease progression, but the cumulative toxicity of the drugs limits the continued use of chemotherapy. continued application. Therefore, how to reduce toxicity and prolong progression-free survival and overall survival while chemotherapy has become critical to the choice of treatment modality. 2014 Arnold Dirk in ESMO suggested that there is no breakthrough in new drugs or new treatment principles for colorectal cancer, and we have fine-tuned the treatment strategy. There is a new consensus on how best to use these treatments for patients – that is, to explore the clinical application of maintenance therapy for colorectal cancer. The main emphasis is on “reduced maintenance”, “single drug maintenance”, “switch maintenance therapy”, “combination maintenance”, etc. concept. Our department is currently using Chinese medicine for maintenance treatment! It has been found that it can significantly down-regulate VEGF expression in the serum of patients with spleen-deficiency tumors and has good anti-intestinal cancer effects in vitro, the main mechanism of which is reversing multidrug resistance of colorectal cancer chemotherapy and anti-neoplastic vascularization. The efficacy of discriminative treatment with the main formula of strengthening the spleen and detoxifying was better than other treatments. mPFS was 11.7 months (vs. 8.2 months in the control group), mOS was 22.6 months (vs. 18.5 months in the control group), which was significantly better than the control group, and the disease control rate was 80.95% (vs. 60.59% in the control group). The improvement rate of TCM symptoms in the Jianshu Detoxification Formula group was 66.67% (vs. 35% in the control group), which significantly improved the quality of life and reduced side effects such as bone marrow suppression. Therefore, the efficacy of the formula for strengthening the spleen and detoxifying the toxin is clear and has good prospects for clinical application.
Praise